Compare Procter & Gamble Co (PG) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Procter & Gamble Co vs GeneDx Holdings Corp — how do they compare? Procter & Gamble Co trades at $149.52 (market cap $344.87B), while GeneDx Holdings Corp trades at $62.68 (market cap $1.83B). The key difference: Procter & Gamble Co is far larger — about 188.5× GeneDx Holdings Corp's market cap, and Procter & Gamble Co pays a 2.94% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| PG | WGS | |
|---|---|---|
Market Cap | $344.87B | $1.83B |
Volume | 6,423,436 | — |
Sector | Consumer Staples | Technology |
52-Week High | $167.18 | $167.51 |
52-Week Low | $138.10 | $34.51 |
Enterprise Value | $370.34B | $1.83B |
Dividend Yield | 2.94% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Procter & Gamble (PG) trades at $149.15, showing minimal daily movement. The stock exhibits neutral technical signals with support near $147 and resistance at $150. Fundamentally, PG maintains stable revenue near $84.3 billion and strong net income margins above 19%, supported by consistent earnings beats. Recent news highlights its dividend reliability amid market volatility, with a 69-year track record of increases. Analyst consensus is bullish with a $160.50 price target, though valuation multiples trade at premiums to peers.
PG offers steady growth with dividend safety but faces near-term headwinds from premium valuations and modest revenue expansion. Upside depends on execution of supply chain efficiencies and sustained consumer demand. Risks include competitive pressures and economic sensitivity. Institutional ownership trends show mixed positioning, reflecting cautious optimism.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% today, amid a bearish technical signal and multiple class-action lawsuits alleging securities fraud. The stock shows weak fundamentals with a negative net income margin of -17.58% and ROE of -30.42%, though it beat EPS estimates in two of the last three quarters. Revenue grew to $427.54M in 2025 but profitability remains a challenge, with a high EV/EBITDA of 161.17 indicating stretched valuation relative to earnings.
Despite a 90.9% analyst buy rating and a $75.40 consensus price target, significant risks from litigation and persistent losses cloud the outlook. The stock faces near-term pressure from legal overhangs, while operational cash flow turned negative in 2026. Investors should weigh high analyst optimism against substantial fundamental and legal headwinds before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
